Trial Profile
A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms DISC
- 24 Jul 2012 Status changed from active, no longer recruiting to completed as reported by UKCRN.
- 31 May 2012 Location (England) added as reported by United Kingdom Clinical Research Network record.
- 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 84% to 88%.